What Cotadutide is
Cotadutide is a dual GLP-1 and glucagon receptor agonist studied for weight and metabolic-disease contexts.
Cotadutide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it sits in the same next-generation multi-agonist category that made retatrutide so interesting.
The useful starting point is to separate the molecule itself from the internet story around it. It sits in the same next-generation multi-agonist category that made retatrutide so interesting.
Why people keep looking it up
It sits in the same next-generation multi-agonist category that made retatrutide so interesting.
Cotadutide is a dual GLP-1 and glucagon receptor agonist studied for weight and metabolic-disease contexts.
Cotadutide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, glucagon receptor, and metabolic signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Early human metabolic signal with ongoing clinical uncertainty.
Human data exists, but it remains clinical-stage rather than an approved mainstream therapy.
Mechanistic support comes from dual incretin and glucagon-pathway biology.
Why this page carries the current tier: Early human metabolic signal with ongoing clinical uncertainty.
The current seed trail for Cotadutide is pulling from 1 literature source, 1 trials source, 1 databases source, and 1 safety source.
Safety, limits, and regulatory context
The category is promising, but investigational metabolic drugs should not be treated like finished products.
Cotadutide remains investigational in the contexts tracked here.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Cotadutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Cotadutide is CID 134694273. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 134694273
- Formula
- C167H252N42O55
- Molecular weight
- 3728.0
- InChIKey
- YEKUUBPJRPXMBM-PTCFZACGSA-N
Matched synonyms include Cotadutide, 1686108-82-6, cotadutida, MEDI0382, MEDI-0382, Medi 0382, QL6A9B13HW, DTXSID601336753.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Cotadutide returns 23 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Cotadutide returns 59 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.